Medication info
Pregalin Capsule 25 mg (Pregabalin)

Pregalin Capsule 25 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Korea United Pharm, Co., Ltd.
Appearance
A hard capsule with a colorless or pale yellow body and white powder inside.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201802254 · Approved 2018.05.30 · Insurance code 642803100

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, in 2 divided doses per day. The total daily dose is expressed as pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5, Patients with renal impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, Discontinuation of treatment). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg per day. The initial dose is 75mg twice daily (150mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg per day). For patients who do not experience sufficient benefit at a dose of 300mg per day, the dose may be increased within 1 week to 225mg twice daily (450mg per day). Although clinical studies have also been conducted at a dose of 600mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150, maximum dose 600, BID or TID ≥30 -<60: Initial dose 75, maximum dose 300, BID or TID ≥15 -<30: Initial dose 25-50, maximum dose 150, QD or BID <15: Initial dose 25, maximum dose 75, QD Supplemental dose after hemodialysis: 25 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under dosing regimen. b: A supplemental dose is an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
There are insufficient safety and efficacy data for children under 12 years of age and adolescent patients aged 12∼17 years; therefore, use is not recommended.

Ingredients

Manufacturer
Korea United Pharm, Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia.
View approved original text

This medication helps relieve peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment for partial seizures in patients with epilepsy. Additionally, it is effective in relieving pain due to fibromyalgia. Aiming to improve the quality of life of patients with these various symptoms.

How to take

Adult dose

This medicine is administered orally, with or without food, in 2 divided doses per day. The total daily dose is expressed as pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section 5, Patients with renal impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, Discontinuation of treatment). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg per day. Based on the response and tolerability of each patient, the dose may be increased to 300mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg per day. The initial dose is 75mg twice daily (150mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150mg twice daily (300mg per day). For patients who do not experience sufficient benefit at a dose of 300mg per day, the dose may be increased within 1 week to 225mg twice daily (450mg per day). Although clinical studies have also been conducted at a dose of 600mg per day, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted unchanged by the kidneys. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosing regimen Initial dose (mg/day) Maximum dose (mg/day) ≥60: Initial dose 150, maximum dose 600, BID or TID ≥30 -<60: Initial dose 75, maximum dose 300, BID or TID ≥15 -<30: Initial dose 25-50, maximum dose 150, QD or BID <15: Initial dose 25, maximum dose 75, QD Supplemental dose after hemodialysis: 25 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under dosing regimen. b: A supplemental dose is an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

There are insufficient safety and efficacy data for children under 12 years of age and adolescent patients aged 12∼17 years; therefore, use is not recommended.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; if depression or mood changes occur during use, inform your healthcare provider immediately. Do not take this medication if you have an allergy to it or have genetic issues like lactose intolerance. Diabetic patients should be cautious as this medication may lead to weight gain, necessitating adjustments in doses of blood glucose controlling medications. If you experience a severe allergic reaction such as angioedema, discontinue use immediately and consult your healthcare provider. Elderly patients should be careful during initial use, as this medication may cause increased dizziness or drowsiness. Visual disturbances or changes may occur during use, which can improve once the medication is stopped. There is insufficient data to make a safe decision about discontinuing other antiepileptic drugs when using this medication as a standalone treatment. Sudden discontinuation of this medication may result in withdrawal symptoms such as insomnia, headaches, and anxiety; it is advisable to taper off gradually in consultation with your healthcare provider. Patients with a history of substance abuse may be at a higher risk of abuse with this medication, so caution is advised when taking it. Patients with compromised renal function may require dosage adjustments for this medication. Patients with heart disease should be careful as there have been reports of congestive heart failure risk associated with this medication. Combining this medication with opioid analgesics may increase the risk of central nervous system depression; special caution is required when used together. Patients with respiratory or neurologic diseases or the elderly may be at a higher risk of severe respiratory depression and may need dosage adjustments. Pregnant women should avoid this medication due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Breastfeeding women should consult their healthcare provider, as this medication can be transmitted through breast milk, and may need to discontinue breastfeeding or the medication. Caution should be taken during dangerous activities such as driving or operating machinery, as dizziness or drowsiness may occur after taking this medication. If symptoms such as rash, fever, or swelling around the lips or eyes occur while taking this medication, discontinue use immediately and inform your healthcare provider. In case of an overdose, symptoms may include drowsiness, confusion, depression, seizures, and immediate treatment at a hospital is required. This medication must be kept out of the reach of children and should not be transferred to other containers.

Side effects

suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper respiratory edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependency, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, depersonalization, sexual sensation disorder, restlessness, anxiety, mood swings, emotional blunting, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, dizziness, drowsiness, ataxia, impaired coordination, balance disorders, memory loss, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech impairment, hypertonia, diminished reflexes, motor abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, action tremor, syncope, confusion, motor retardation, olfactory abnormalities, loss of taste, writing impairment, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, eye edema, decreased vision, ocular pain, eye fatigue, increased tear secretion, eye irritation, mydriasis, during vibration, change in depth perception of vision, strabismus, brightness of the visual field, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, swelling, gait abnormalities, falls, a feeling of drunkenness, sensory abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, fatigue, delirium, paralysis, mood disorders, drowsiness, state of confusion, depression, agitation, restlessness, seizures, mood disorders, drowsiness, state of confusion, depression, agitation, restlessness, seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture from entering, in a cool place between 15 to 30 degrees Celsius. Proper storage ensures the medication retains its effectiveness.

Appearance and packaging

Appearance

A hard capsule with a colorless or pale yellow body and white powder inside.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.